It didn’t take long for an audience of public health professionals focused on antibiotic resistance to find a silver lining in the Nov. 8 election results: the GOP victories mean that there is a very real chance for enactment of a “wildcard” patent extension to support development of drugs for emerging infections.
The organizers of a Nov. 9 Duke Margolis Center workshop on incentives for antibiotic development probably expected a very different...